

Vanda Pharmaceuticals Inc.  
 Form 4  
 November 08, 2006

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Clark William D

(Last) (First) (Middle)  
 9605 MEDICAL CENTER DRIVE, SUITE 300  
 (Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 Vanda Pharmaceuticals Inc. [VNDA]

3. Date of Earliest Transaction (Month/Day/Year)  
 11/07/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 Sr VP, Chief Business Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	11/07/2006		M		400 A \$ 0.33	400	D
Common Stock	11/07/2006		S		200 D \$ 11.5	200	D
Common Stock	11/07/2006		S		200 D \$ 11.61	0	D
Common Stock	11/08/2006		M		18,600 A \$ 0.33	18,600	D
Common Stock	11/08/2006		S		3,202 D \$ 11	15,398	D

## Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Common Stock	11/08/2006	S	700	D	\$ 11.02	14,698	D
Common Stock	11/08/2006	S	99	D	\$ 11.03	14,599	D
Common Stock	11/08/2006	S	200	D	\$ 11.04	14,399	D
Common Stock	11/08/2006	S	700	D	\$ 11.05	13,699	D
Common Stock	11/08/2006	S	400	D	\$ 11.07	13,299	D
Common Stock	11/08/2006	S	400	D	\$ 11.08	12,899	D
Common Stock	11/08/2006	S	300	D	\$ 11.1	12,599	D
Common Stock	11/08/2006	S	199	D	\$ 11.13	12,400	D
Common Stock	11/08/2006	S	935	D	\$ 11.15	11,465	D
Common Stock	11/08/2006	S	300	D	\$ 11.16	11,165	D
Common Stock	11/08/2006	S	99	D	\$ 11.18	11,066	D
Common Stock	11/08/2006	S	200	D	\$ 11.19	10,866	D
Common Stock	11/08/2006	S	102	D	\$ 11.2	10,764	D
Common Stock	11/08/2006	S	200	D	\$ 11.21	10,564	D
Common Stock	11/08/2006	S	100	D	\$ 11.22	10,464	D
Common Stock	11/08/2006	S	680	D	\$ 11.23	9,784	D
Common Stock	11/08/2006	S	299	D	\$ 11.24	9,485	D
Common Stock	11/08/2006	S	1,120	D	\$ 11.25	8,365	D
Common Stock	11/08/2006	S	380	D	\$ 11.26	7,985	D
Common Stock	11/08/2006	S	700	D	\$ 11.3	7,285	D
	11/08/2006	S	100	D		7,185	D

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Common Stock					\$	11.33	
Common Stock	11/08/2006	S	300	D	\$	11.34	6,885 D
Common Stock	11/08/2006	S	286	D	\$	11.35	6,599 D
Common Stock	11/08/2006	S	200	D	\$	11.36	6,399 D
Common Stock	11/08/2006	S	99	D	\$	11.39	6,300 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 0.33	11/07/2006		M	400	<u>(1)</u> 09/01/2014	Common Stock 400
Employee Stock Option (right to buy)	\$ 0.33	11/08/2006		M	18,600	<u>(1)</u> 09/01/2014	Common Stock 18,600

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Clark William D  
9605 MEDICAL CENTER DRIVE  
SUITE 300  
ROCKVILLE, MD 20850

Sr VP, Chief Business Officer

## Signatures

/s/ William D.  
Clark

11/08/2006

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable with respect to 49,653 of the shares covered by the option immediately. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.